@inbook{7bcecbe7ea654a738dfbdff70818a946,
title = "Pharmaceutical strategies for reducing ldl-c and risk of cardiovascular disease",
keywords = "Alirocumab, Atherogenic dyslipidaemia, Atherosclerosis, Atorvastatin, Bococizumab, Canakinumab, Cardiovascular disease, Combination therapy, Evolocumab, Ezetimibe, Ezetimibe-atorvastatin therapy, Familial hypercholesterolaemia (FH), Fenofibrate, Hyper-cholesterolaemia, Inclisiran, Ischaemic stroke, Low-density lipoprotein cholesterol (LDL-C), Low-dose methotrexate, Myocardial infarction, PCSK9 inhibition therapy, Polypill, Proprotein convertase subtilisin/kexin type 9 (PCSK9), Ribonucleic acid (RNA), Rosuvastatin, Simvastatin, Small interfering ribonucleic acid, Statin intolerance, Statin potency, Statin-ezetimibe combination therapy, Statin-fibrate combinations, Statins, Unstable angina",
author = "Catapano, \{Alberico L.\} and Laie Tokgozoglu and Silva, \{Alberto Melloe\} and Eric Bruckert",
year = "2023",
month = jun,
day = "23",
language = "English",
isbn = "9789814877459",
pages = "305--316",
booktitle = "Advances in Surgical and Medical Specialties",
publisher = "Taylor and Francis",
address = "Australia",
}
SKH 3 Sağlık ve Kaliteli Yaşam